DAX24.853 ±-0,0%Est506.011 -0,4%MSCI World4.343 -0,1%Top 10 Crypto8,3200 -2,6%Nas22.597 -2,0%Bitcoin55.519 -1,6%Euro1,1869 -0,1%Öl67,67 -2,8%Gold4.922 -3,2%
Beliebte Suche
DAX 40 Ölpreis Euro - Dollar Bitcoin - Euro Goldpreis
Meistgesucht
Siemens Energy ENER6Y Siemens 723610 Mercedes-Benz Group (ex Daimler) 710000 SAP 716460 Deutsche Telekom 555750 Rheinmetall 703000 NVIDIA 918422 BASF BASF11 Gerresheimer A0LD6E Amazon 906866 Lufthansa 823212 Microsoft 870747 Allianz 840400 Bayer BAY001 DroneShield A2DMAA
Alle Aktien für 0 Euro (zzgl. Spreads) handeln mit finanzen.net zero. Hier informieren
Heute im Fokus
DAX letztlich kaum bewegt -- US-Börsen rot -- Mercedes-Benz: Gewinneinbruch -- Siemens erhöht Ergebnisprognose -- TKMS, Deutsche Börse, DroneShield, Birkenstock, Micron, Palantir, Fastly im Fokus
Top News
Analysten: Gold und Silber werden immer mehr zu einem Spekulationsobjekt Analysten: Gold und Silber werden immer mehr zu einem Spekulationsobjekt
Gefährliche Streaming-Reichweite: Wie Netflix-Dokus Aktien von VW, Boeing & Co. zum Absturz bringen Gefährliche Streaming-Reichweite: Wie Netflix-Dokus Aktien von VW, Boeing & Co. zum Absturz bringen
Suche...
Login
ODER

Neu auf finanzen.net?

Kostenfrei registrieren und Vorteile nutzen

Übersicht Wertpapierdepots Musterdepots Watchlists Meine News Newsletter Forum Trading Desk Apps Social Media Podcasts
Profil
Wer­bung
Noch bis 14. April bei der Commerzbank gebührenfrei in Vanguard-ETFs investieren

Immunic Aktie

Kaufen
Verkaufen
Immunic Aktien-Sparplan
0,7360 EUR +0,1220 EUR +19,87 %
BMN
0,8800 USD +0,1263 USD +16,76 %
BTT
Immunic jetzt ohne Ordergebühren (zzgl. Spreads) handeln beim ‘Kostensieger’ finanzen.net zero (Stiftung Warentest 12/2025)
Smartphone

Marktkap.80,52 Mio. EUR

Div. Rendite0,00%
WKN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

WKNA2PHD4

ISIN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

ISINUS4525EP1011

Symbol wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

SymbolIMUX

Immunic Aktien News

DatumMeistgelesen
EQS GroupEQS-News: Immunic to Present Additional Phase 2 CALLIPER Trial Data for Vidofludimus Calcium at the ACTRIMS Forum 2026, Reinforcing Its Potential in Progressive Multiple Sclerosis
EQS GroupEQS-News: Immunic Highlights 2025 Accomplishments and Upcoming Milestones
PR NewswireImmunic Highlights 2025 Accomplishments and Upcoming Milestones
Wer­bungImmunic-Aktie für 0 Euro (zzgl. Spreads) handeln bei finanzen.net zero
EQS GroupEQS-News: Immunic to Participate in the 8th Annual Evercore ISI Healthcare Conference in December
PR NewswireImmunic to Participate in the 8th Annual Evercore ISI Healthcare Conference in December
EQS GroupEQS-News: Immunic, Inc. Reports Third Quarter 2025 Financial Results and Provides Corporate Update
PR NewswireImmunic, Inc. Reports Third Quarter 2025 Financial Results and Provides Corporate Update
EQS GroupEQS-News: Immunic to Participate in Industry and Investor Conferences in November
PR NewswireImmunic to Participate in Industry and Investor Conferences in November
EQS GroupEQS-News: Immunic to Participate in Scientific and Investor Conferences in October
PR NewswireImmunic to Participate in Scientific and Investor Conferences in October
EQS GroupEQS-News: Immunic Presented Key Vidofludimus Calcium Data at the 41st Congress of ECTRIMS, Highlighting Its Potential in Multiple Sclerosis
PR NewswireImmunic Presented Key Vidofludimus Calcium Data at the 41st Congress of ECTRIMS, Highlighting Its Potential in Multiple Sclerosis
EQS GroupEQS-News: Immunic Receives Notice of Allowance for United States Patent Protecting Vidofludimus Calcium's Dose Strengths in Progressive Multiple Sclerosis
PR NewswireImmunic Receives Notice of Allowance for United States Patent Protecting Vidofludimus Calcium's Dose Strengths in Progressive Multiple Sclerosis
EQS GroupEQS-News: Immunic to Participate in Investor and Scientific Conferences in September
PR NewswireImmunic to Participate in Investor and Scientific Conferences in September
EQS GroupEQS-News: Immunic, Inc. Reports Second Quarter 2025 Financial Results and Provides Corporate Update
PR NewswireImmunic, Inc. Reports Second Quarter 2025 Financial Results and Provides Corporate Update
EQS GroupEQS-News: Immunic Reports New, Positive Long-Term Open-Label Extension Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis
PR NewswireImmunic Reports New, Positive Long-Term Open-Label Extension Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis
PR NewswireImmunic Announces Completion of Enrollment for Both Phase 3 ENSURE Trials in Relapsing MS and Presents Additional Data Underlining Positive Outcome of Phase 2 CALLIPER Trial in Progressive MS
EQS GroupEQS-News: Immunic to Participate in Investor, Scientific and Industry Conferences in June
PR NewswireImmunic to Participate in Investor, Scientific and Industry Conferences in June
EQS GroupEQS-News: Immunic to Participate in Scientific and Industry Conferences in May
PR NewswireImmunic to Participate in Scientific and Industry Conferences in May
EQS GroupEQS-News: Immunic Announces Vidofludimus Calcium Reduced Risk of Disability Worsening by 30% in Primary Progressive Multiple Sclerosis Patients from Phase 2 CALLIPER Trial
PR NewswireImmunic Announces Vidofludimus Calcium Reduced Risk of Disability Worsening by 30% in Primary Progressive Multiple Sclerosis Patients from Phase 2 CALLIPER Trial
EQS GroupEQS-News: Immunic, Inc. Announces Closing of $5.1 Million Registered Direct Offering, Led by Aberdeen Investments
EQS GroupEQS-News: Immunic, Inc. Announces Pricing of $5.1 Million Registered Direct Offering, Led by Aberdeen Investments
EQS GroupEQS-News: Immunic, Inc. to Participate in Scientific and Industry Conferences in April
PR NewswireImmunic, Inc. to Participate in Scientific and Industry Conferences in April
EQS GroupEQS-News: Immunic to Participate in Scientific and Investor Conferences in March
PR NewswireImmunic to Participate in Scientific and Investor Conferences in March
EQS GroupEQS-News: Immunic Presents Key Vidofludimus Calcium Data at the ACTRIMS Forum 2025, Highlighting Its Potential in Multiple Sclerosis
PR NewswireImmunic Presents Key Vidofludimus Calcium Data at the ACTRIMS Forum 2025, Highlighting Its Potential in Multiple Sclerosis
EQS GroupEQS-News: Immunic’s Oral IMU-856 Demonstrated Dose-Dependent Increase of GLP-1 in Celiac Disease Patients and Corresponding Effects in Preclinical Testing
PR NewswireImmunic's Oral IMU-856 Demonstrated Dose-Dependent Increase of GLP-1 in Celiac Disease Patients and Corresponding Effects in Preclinical Testing
EQS GroupEQS-News: Immunic to Participate in Investor and Scientific Conferences in February
PR NewswireImmunic to Participate in Investor and Scientific Conferences in February

Immunic News

Immunic News: auf dieser Seite finden Sie alle Immunic News und Nachrichten zur Immunic Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Immunic News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Immunic News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.